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Objective/background: The GeneXpert MTB/RIF assay (Xpert) was endorsed as the initial
diagnostic tool in people suspected of human immunodeficiency virus-associated or
drug-resistant tuberculosis (TB). However, information regarding the performance of Xpert
for diagnosing smear-negative TB in high burden settings remains limited. We evaluated
the diagnostic accuracy of Xpert and the impact of bleach concentration on the perfor-
mance of Xpert using smear-negative sputum samples from human immunodeficiency
virus-negative patients.
Methods: One spot and one morning smear-negative sputum samples per patient were
examined using Xpert and culture at the Mycobacteriology Research Center of Jimma
University, Ethiopia. The sputum culture on both Lo¨wenstein–Jensen and/or Mycobacteria
Growth Indicator Tube was the gold-standard.
Results: Of 185 smear-negative presumptive pulmonary TB cases, 19 (10.3%) had culture-
proven TB. The sensitivity of Xpert on spot and morning sputum was similar (63.2%). Test-
ing two specimens per patient insignificantly increased the sensitivity of Xpert. Bleach con-
centration and pelleting improved the sensitivity of Xpert over unprocessed sputum in
paired samples (73.8% vs. 63.2%) without affecting the specificity (95%). Bleach concentra-
tion and pelleting allowed an additional seven cases of TB (missed on the first and second
direct Xperts) to be detected, five of which were from culture-negative cases.
Conclusion: Testing of a single sputum sample by Xpert can reach reasonable sensitivity
and results would be available on the same day, avoiding loss of patients and treatment
delay. The sensitivity of Xpert was improved after bleach concentration and pelleting,
although its added value needs further study on a larger scale.
 2016 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.316 26 24;
212 I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 5 ( 2 0 1 6 ) 2 1 1 –2 1 8Introduction
Tuberculosis (TB) remains a major public health problem,
accounting for 9 million incident cases and 1.5 million deaths
worldwide [1]. Ethiopia ranks 10th among the 22 countries
with a high TB burden [2,3]. Recently, the number of regis-
tered smear-negative TB cases transcended the smear-
positive cases. This is a peculiar situation seen in Ethiopia
for over a decade. In the national TB prevalence survey in
2010/11 smear-negative cases accounted for 57% of culture-
positive cases [4]. Diagnosis of smear-negative pulmonary
TB remains a challenge [3,5,6]. This is because of the lack of
rapid and accurate diagnostic modalities that can be applied
in resource-limited settings [3,7].
The GeneXpert MTB/RIF assay (Cepheid, Sunnyvale, CA,
USA; hereafter referred to as Xpert) detects the presence of
MTB complex (MTBC) and its resistance to RIF in a single reac-
tion [8,9]. Xpert is an integrated fully automated specimen
processing and nucleic acid-amplification test [8,10], strongly
recommended byWorld Health Organization for the diagnosis
of human immunodeficiency virus (HIV)-associated TB and
multidrug-resistant TB [11]. In clinical evaluation studies,
the sensitivity of Xpert in patients with smear-negative pul-
monary TB was reported to be moderate, 55–86%, compared
with 99–100% in patients with smear-positive TB [12–14]. This
urges for a simple and efficient way to enhance the sensitivity
of Xpert for detection of MTB in smear-negative patients.
House hold sodium hypochlorite (NaOCl) or bleach has
been used for over a century to increase the yield of micro-
scopic detection. Bleach at 5% concentration can digest the
sputum products and inactivate the mycobacteria without
altering their structures. This provides a greater safety for
laboratory use. Further centrifugation or sedimentation con-
centrates the acid fast bacilli (AFB) in the mixture, increasing
the rate of positivity [15]. In the current study, we primarily
evaluated the diagnostic accuracy of direct Xpert test in
smear-and HIV-negative patients. Secondly, we determined
whether sputum processing using bleach combinedwith sim-
ple centrifugation can increase the sensitivity of Xpert in
resource poor settings.
Materials and methods
Study participants
A cross-sectional prospective study was carried out at Jimma
University Specialized Hospital, a public tertiary care hospital,
in Southwest Ethiopia. Adult consecutive patients with
presumptive pulmonary TB presenting at the health care
facility were screened between February 2014 and August
2014. Inclusion criteria were based on the World Health Orga-
nization case definition for presumptive pulmonary TB [16]
and included patients having a persistent cough for at least
2 weeks with or without one of the following: night sweats,
unintentional weight loss, fever, chest pain, shortness of
breath, loss of appetite, and contact with a TB patient.
Consenting patients were enrolled only if they had
three sputum-negative results on smear microscopy, wereHIV-negative, and could provide detailed clinical history along
with adequate amount of sputum specimen. Demographic
and clinical characteristics were collected through interview
by using a pretested questionnaire. This study was approved
by institutional review boards of Jimma University, Ethiopia
(reference number: RPGC/510/2014). All participants gave
written consent for use of routine clinical data for research
purposes.
Sputum sample processing
A portion of the collected sputum specimen was used imme-
diately for direct smear microscopy and the remaining
portion was stored at 4 C in a refrigerator for culture and
Xpert. HIV test results were collected from the medical
records after obtaining written consent from the clients.
One spot and one morning sputum sample collected from
each presumptive TB case were brought to room temperature
and liquefied by N-acetyl L-cysteine (NALC) powder. Each
sputum sample was then divided into two aliquots, which
were carefully labeled and assayed independently in a
blinded manner by a second person. The first aliquot of spot
sputum was assayed for direct Xpert and the other aliquot
for culture (Mycobacteria Growth Indicator Tube [MGIT 960]
and Lo¨wenstein–Jensen [LJ] medium). Likewise, the first
aliquot of morning sputum was tested for direct Xpert and
the second for bleach-concentrated Xpert.
Direct Xpert
Xpert was performed as previously described [8]. Sample
reagent was added to the sputum specimens in a 2:1 ratio
in a sterile falcon tube. The solution was vortexed and left
to settle for 15 min, with vortexing halfway through. The
supplied sterile transfer pipette was used to draw the lique-
fied sample up to the marked line (corresponding to 2 mL)
and transferred to a cartridge. The Xpert cartridge was then
loaded onto the Xpert machine (Cepheid, Dx System Version
4.0c). Results were reported as positive or negative for MTBC.
RIF resistance results were reported as susceptible, resistant,
or indeterminate.
Sputum culture and identification
Mycobacterial culture was done in MGIT 960 and on LJ med-
ium. Sputa were decontaminated by the standard N-acetyl-
L-cysteine and sodium hydroxide (NALC/NaOH) method with
a final NaOH concentration of 1% [17]. An equal volume of
standard NALC/NaOH solution was added to the specimen
and incubated for 15 min at room temperature. After centrifu-
gation for 15 min at 3000g, the sediment was resuspended in
1 mL of sterile phosphate buffered saline (PBS; pH 6.8). The
resulting pellet was used to inoculate a MGIT 960 and LJ tube.
The MTB H37Rv reference strain (American Type Culture
Collection 27294) was processed with each run as a positive
control. All positive cultures were confirmed for MTBC with
SD Bioline MPT64TB Ag test (Standard Diagnostics, Yongin,
South Korea).
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Xpert from bleach-treated and concentrated sputum was car-
ried out according to the optimized protocol in the validation
experiment of this study (described hereunder). Briefly, the
second part of the morning specimen was transferred
to a conical centrifuge tube (15 mL; Sarstedt, Nu¨mbrecht,
Germany) and treated with an equal volume of 5% bleach
(Chora Gas and Chemical Products Factory, Addis Ababa,
Ethiopia). After mixing, the tube was left for 15 min at room
temperature and shook for 30 s every five minutes. The PBS
was added up to 15 mL and centrifuged at 3000g for 15 min
using a simple centrifuge (a low-cost table-top centrifuge that
is available in peripheral laboratories of Ethiopia). After cen-
trifugation the supernatant was decanted carefully and the
sediment was resuspended with 1 mL of sterile PBS
(pH = 6.8). The sample reagent was added in a 3:1 ratio and
shaken vigorously for 15 s. Subsequently, the procedure
described for direct Xpert was followed [8].
Statistical analysis
Data were analyzed using SPSS version 20.0 (SPSS Inc.,
Chicago, IL, USA). Sensitivity, specificity, positive predictive
value, and negative predictive value of Xpert and their respec-
tive 95% confidence intervals (CI) were calculated using a
culture as reference standard. A positive culture result was
defined as growth on LJ and/or in MGIT identified as MTB.
We excluded data of patients with contaminated sputum
culture results and indeterminate Xpert results from the diag-
nostic accuracy analysis. The study reporting conforms to the
Standards for Reporting Diagnostic Accuracy guidelines for
diagnostic accuracy reporting (www.stard-statement.org/).
Validation experiments
Effect of bleach-sputum processing on Xpert
The protocol was based on the pretreatment of the sputum
sample with 5% bleach. It is known that house hold bleach
(sodium hypochlorite) can digest and liquefy mucus and
debris in sputum [15]. This releases the TB bacilli, which
can be further concentrated by centrifugation. Two experi-
ments were conducted to check whether the pretreatment
of sputum with bleach could have an interfering effect on
Xpert result.
In the first experiment, a total of 10 AFB-negative sputum
samples (n = 10) spiked with the MTB H37Rv reference strain
were included. Briefly, H37Rv was cultured on LJ medium.
Using a sterile wire loop, three to five well-isolated colonies
were emulsified in 3 mL of sterile physiological saline (0.9%
weight/volume). The bacterial suspension’s turbidity was
matched with that of McFarland Number 0.5 (approximately
1  108 colony forming units/mL). This suspension was spiked
into 2 mL of liquefied (kept overnight at room temperature)
smear-negative sputum from a healthy volunteer. Each
spiked sample was divided in two groups: one received the
treatment with 5% bleach followed by centrifugation (3000g
for 15 min) and the other did not receive any treatment with
bleach, nor centrifugation. Bleach-treated and untreatedsamples were analyzed by Xpert (as per the manufacturer’s
instruction). Positive results were placed in one of four
categories: very low, low, medium, or high based on the quan-
titative cycle threshold (Ct) value of probe A.
The experiment was expanded by testing known smear-
positive sputum specimens (n = 9). The sputum samples were
kept at room temperature for 24 h to allow liquefaction. This
enabled us to split the sample into two equal parts (approxi-
mately 1 mL each). As in the case of spiked sputum, the first
part was treated with 5% bleach and the other left untreated.
Bleach-treated and bleach-untreated samples were tested
with Xpert.
Validation results
A total of 19 paired (bleach-treated and bleach-untreated)
samples were analyzed with Xpert. The test result showed
that all bleach-untreated samples (10 H37Rv spiked smear-
negative and nine smear-positive sputa) and 18 bleach-
treated samples (nine H37Rv spiked smear-negative and nine
smear-positive sputa) were Xpert positive. The result for one
of the bleach-treated spiked sputum samples was un-
interpretable (error). The mean Ct value was 13.77 for
bleach-untreated and 14.90 for bleach-treated specimens.
Bleach-treatment and centrifugation did not seem to affect
Ct values (t-test values of 0.800 and 0.460 for spiked and natu-
rally infected sputa; Table 1). We concluded that 5% bleach did
not have an interfering effect on Xpert test results, although
more studies are warranted to further validate the protocol.
Results
Characteristics of study participants
During the study period, a total 326 consecutive adult patients
with presumptive pulmonary TB were screened. One hundred
twenty-four patients were excluded from the study (56 were
HIV-positive/unknown, 30 were smear positive, 19 provided
a sample with inadequate volume, 13 did not provide three
sputa, and six hadmissing AFB-smear results). Of the remain-
ing 202 presumptive TB patients who had smear-negative
sputum, 17 patients were excluded (13 culture contaminated
and four Xpert MTB/RIF indeterminate results), leaving 185
patients for the final analysis. Overall study flow diagram is
shown in Fig. 1. The majority, 61.6% (114/185), of study partic-
ipants were men. The median age of patients was 38 years
(inter-quartile range 23–55). The study participant character-
istics are shown in Table 2.
Diagnostic accuracy of direct Xpert
Nineteen (10.3%) of 185 smear-negative presumptive cases
had culture (LJ and/or MGIT) confirmed TB. Among the 185
screened, 7.6% tested positive on the first Xpert and an addi-
tional 1.6% on the second Xpert, if no pretest bleach treat-
ment was performed. Using mycobacterial culture as the
reference standard, the sensitivity of Xpert in spot and morn-
ing sputumwas the same (63.2% [95% CI: 41.5–84.8]). However,
when results of both spot andmorning Xpert were considered
Table 1 – Pre-study Xpert validation results using paired artificially spiked smear-negative and naturally smear-positive
sputum samples with or without pre-test bleach treatment.
Code Sputum appearance Bleach untreated Bleach treated Paired t-test
Result Ct value Result Ct value p
H37Rv spiked sputum
3830 Purulent Positive 13.4 Positive 16.6 .080
3854 Bloody Positive 14.8 Positive 14.7
3830 Purulent Positive 13.7 Error –
3864 Muco purulent Positive 14.9 Positive 15.6
3852 Purulent Positive 12.9 Positive 12.5
3830 Purulent Positive 15.6 Positive 17.4
3854 Purulent Positive 15.6 Positive 16.3
3839 Muco purulent Positive 19.7 Positive 19.1
3846 Muco purulent Positive 9.7 Positive 10.9
3846 Highly mucoid Positive 10.4 Positive 16.5
Smear positive sputum
3558 Muco purulent Positive 15.8 Positive 20.5 .460
3560 Purulent Positive 16.2 Positive 14.3
3577 Muco purulent Positive 10.6 Positive 10.9
3608 Muco purulent Positive 13.5 Positive 12.7
3612 Purulent Positive 12.7 Positive 16.6
3669 Purulent Positive 10.0 Positive 9.0
3778 Muco purulent Positive 12.6 Positive 15.2
3788 Muco purulent Positive 13.9 Positive 18.4
3836 Purulent Positive 15.7 Positive 11.0
Note: Ct = cycle threshold.
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increased compared with either test alone, although the dif-
ference was not statistically significant (p value = .76). Among
166 culture-negative cases, two spot and four morning sputa
were Xpert positive. The estimated specificity of Xpert was
98.8% in spot and 97.6% in morning sputum samples. A sum-
mary of the overall Xpert performance is depicted in Table 3.
Performance of Xpert on bleach-concentrated sputum
Twenty-two (12%) of the 185 patients with smear-negative
sputum were positive using bleach-concentrated Xpert, with
eight of them (36.4%) being culture negative. The sensitivity
of a single direct Xpert for culture-confirmed TB was 63.2%
(95% CI: 41.5–84.8) and rose to 73.8% (95% CI: 58.6–97) for
bleach-treated samples, which is also higher than the sensi-
tivity when testing two samples by direct Xpert (68.4% [95%
CI: 47.5–89.3]). Bleach-concentration and pelleting allowed
an additional seven cases of TB (missed on the first and sec-
ond direct Xperts) to be detected, five of which were from
culture-negative cases.
The specificity of Xpert was not significantly affected by
bleach concentration and pelleting: 95.1% (95% CI: 92–98.4)
for bleach-concentrated sputum versus 98.8% (95% CI:
97–100) and 97.6% (95% CI: 95–100) for direct Xpert in spot
and morning sputa (p = .92). However, the positive predictive
value was lower for bleach-processed sputum (63.6% [95% CI:
43.5–83.7]) compared with unprocessed spot (85.7% [95% CI:
63.4–100]) and morning (75% [95% CI: 53.8–96.2]) sputa (data
not shown). There were five patients, whose cultures grew
nontuberculous mycobacteria (NTM). One of these patients
had a positive Xpert after bleach concentration and pelleting.There was no RIF resistance detected in any of the sputum
samples tested by Xpert.
Indeterminate Xpert results
Higher numbers of invalid Xpert results were observed when
using bleach-concentrated sputum samples compared with
unprocessed samples (1.5% [3/202] vs. 0.3% [1/404]). Overall,
Xpert was indeterminate in four of 606 tests performed
(0.6%), a rate that was much lower than the overall culture-
contamination rate of 5% (20 of 404 cultures, seven on both
media, four only in MGIT, and two only on LJ). Three
Xpert-indeterminate samples were culture negative and one
was culture positive.
Discussion
Smear-negative pulmonary TB constitutes a major burden of
undiagnosed TB in resource poor settings [7]. It is associated
with poor treatment outcomes, including death due to
delayed diagnosis or nondiagnosis [3,7]. Multiple studies have
consistently shown that Xpert can identify a substantial
proportion of smear-negative TB patients, particularly in
HIV coinfected patients [9,12,18]. There is a paucity of data
on the diagnostic accuracy of the Xpert in smear- and
HIV-negative patients in areas of high TB prevalence such as
Ethiopia.
Our study suggests that application of Xpert on a single
smear-negative sputum specimen can substantially increase
the yield of confirmed TB cases. This is consistent with those
reported by others regarding the effectiveness of Xpert in
accurately detecting the presence of MTB in smear-negative
326 consecutive adult patients screened
Inclusion criteria: Suspicion of pulmonary TB, 
age >18 y, provision of informed consent
202 smear-negative patients were eligible 
124 patients were excluded
56 were HIV-positive/unknown 
30 were smear positive 
19 had sample with inadequate volume
13 did not provide three sputa 
6 had missing AFB-smear result
Sputum 1 (Spot) Sputum 2 (Morning)
1st Xpert MTB/RIFa
Culture (MGIT & LJ)
2nd Xpert MTB/RIFb
Bleach-Xpert MTB/RIFc
17 excluded
13 were culture contaminated 
4 indeterminate Xpert MTB/RIF result
185 patients were considered for sensitivity 
and specificity calculations
MTB culture negative (n = 166)MTB culture positive (n = 19)
a First Xpert positive (n = 12)
b Second Xpert positive (n = 12) 
First + second Xpert positive (n = 13)
c Bleach Xpert positive (n = 14)
a First Xpert positive (n = 2)
b Second Xpert positive (n = 4) 
First + second Xpert positive (n = 4)
c Bleach Xpert positive (n = 8)
Fig. 1 – Overall study flow diagram explaining participants’ recruitment, sample processing, and diagnostic test results. Note.
AFB = acid fast bacilli; HIV = human immunodeficiency virus; LJ = Lo¨wenstein–Jensen; MGIT = Mycobacteria Growth Indicator
Tube; MTB =Mycobacterium tuberculosis; RIF = Rifampicin; TB = tuberculosis; y = year. aXpert test on spot sputum. bXpert test
on morning sputum. cXpert test on bleach-treated and concentrated sputum.
Table 2 – Demographic and clinical characteristics of the 185 study Participants.
Characteristics Smear-negative presumptive pulmonary TB cases p
All patients (n = 185) Culture positive (n = 19) Culture negative (n = 166)
Age, median (IQR) 38 (23–55) 32 (21–47) 40 (26–56) .27
Male sex 114 (61.6%) 14 (73.7%) 100 (60.2%) .25
Taking antibiotics in the last 2 wk 106 (57.3%) 11 (58%) 95 (57.2%) .95
TB contact history in the last 2 y 38 (20.5%) 6 (31.6%) 32 (19.3%) .21
Presenting TB symptom
Cough > 4 wk 93 (50.3%) 13 (68.4%) 80 (48.2%) .09
Chest pain 134 (72.4%) 16 (84.2%) 118 (71%) .22
Night sweats 131 (70.8%) 14 (73.7%) 117 (70.5%) .77
Fever 75 (40.5%) 9 (47.4%) 66 (39.8%) .52
Weight loss 111 (60%) 15 (79%) 96 (58%) .07
Shortness of breath 123 (66.5%) 12 (63.2%) 111 (67%) .75
Loss of appetite 129 (69.7%) 15 (79%) 114 (68.7%) .35
Note: IQR = interquartile range; TB = tuberculosis; wk = week; y = year.
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Table 3 – Diagnostic Performance of Xpert MTB/RIF assay compared with culture as a reference standard, stratified to the type
of sample or number of samples tested per patient.
Index test (Xpert MTB/RIF) Reference standard Sensitivity (95% CI) Specificity (95% CI)
Positive Negative
One spot sputum
Positive 12 2 63.2% (41.5–84.8) 98.8% (97.1–100)
Negative 7 164
One morning sputum
Positive 12 4 63.2% (41.5–84.8) 97.6% (95.3–99.9)
Negative 7 162
Bleach-concentrated pellet (morning)
Positive 14 8 73.8% (53.8–93.5) 95% (91.9–98.4)
Negative 5 158
Two sputa (spot + morning)
Positive 13 4 68.4% (47.5–89.3) 97.6% (95.3–99.9)
Negative 6 162
Three sputa (2 direct + 1 pellet)
Positive 15 9 78.9% (60.6–97.3) 94.6% (91.1–98.0)
Negative 4 157
Note: Mycobacterium tuberculosis culture positivity was used as reference standard, defined as identification of M. tuberculosis in at least one
positive standard sputum culture (either on Lo¨wenstein–Jensen slopes or Mycobacteria Growth Indicator Tube culture). CI = confidence
interval.
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(63.2%) for smear-negative TB is comparable with reported
sensitivities ranged from 61% to 71.7% [13,18,20,21]. Repeating
Xpert test using a different sputum specimen per patient
insignificantly increased the sensitivity. In high TB prevalence
settings such as Ethiopia, repeating Xpert test may increase
laboratory workload and expenses, though further study is
warranted to ascertain the incremental yield from the second
Xpert test.
There is no published data to the best of our knowledge
that evaluated the performance of Xpert using bleach-
concentrated sputum samples. Previous studies demon-
strated nonsignificant improvement in sensitivity of Xpert
when sputum samples were centrifuged [22,23]. We
documented an increased sensitivity by simple bleach con-
centration and pelleting of sputum samples, allowing the
detection of seven cases who would have been missed by
two direct Xperts. Similar to most previous studies performed
the specificity was high for Xpert, ranging from 97% to 100%
[13,23,24]. The difference in specificity of Xpert after bleach
concentration and pelleting was not statistically significant
from direct testing. Sodium hypochlorite (NaOCl) is cheap
and available almost anywhere as household bleach. As a
potent disinfectant, NaOCl also has the advantage of limiting
the risk of laboratory infection. In addition, the relative
centrifugal force needed for concentration of mycobacteria
can easily be achieved by low-cost table-top centrifuge
affordable under existing conditions of most TB laboratories
in developing countries equipped with an Xpert device.
However, bleach concentration and pelleting increased the
rate of Xpert indeterminate test results. This might be due
to the sputum being overconcentrated after centrifugation,
generating viscous mixture debris and the NaOCl blocking
the channels in the cartridge.
In our study, Xpert on bleach-concentrated sputum
detected eight cases from smear-negative TB suspects whichwere not picked up by either of the culture methods. Simi-
larly, in the study by Rachow and colleague [18], 9% of
culture-negative but Xpert-positive patients were classified
as clinical TB cases, with documented positive responses to
anti-TB treatment. Unfortunately, due to logistic constraints,
the eight cases in our study were not followed. As it is of
paramount importance to ascertain that these cases detected
only by Xpert in bleach-concentrated sputum are unambigu-
ously true TB cases, a more thorough clinical evaluation study
which specifically addresses such cases is warranted. Among
culture-positive cases four were identified as NTM using the
SD Bioline MPT64TB Ag test, one of which was positive on
Xpert after bleach concentration. Previous studies by Moure
et al. [13] and Marlowe et al. [25] reported 100% specificity of
Xpert with 20 and 41 NTM samples, respectively. In the
current study, due to limited resources, differentiation of
NTM from MTBC was done by SD Bioline MPT64TB Ag test.
It is possible that due to low MPT64 antigen expression by
some lineage of MTBC, the SD Bioline MPT64TB Ag test can
be false negative. If this is assumed true, the specificity of
Xpert for NTM would be 100% in our study.
We documented a moderate sensitivity (63.2%) of single
direct Xpert among smear-negative culture-positive cases.
Xpert identified majority of the culture confirmed cases with
high specificity. This gives the clinician sufficient confidence
to initiate anti-TB treatment when Xpert is positive. A nega-
tive Xpert does not exclude a diagnosis of smear-negative
TB given the fact that the test was unable to identify 36.8%
of patients with culture confirmed TB. Patients with a high
clinical probability of TB despite a negative Xpert should be
started on anti-TB treatment. It is important to ensure that
clinicians are aware of the Xpert limitations prior to its
implementation. Despite this, Xpert has distinct advantages
over culture; a faster turn-around time, providing same-day
diagnosis which could potentially limit loss to follow-up
during diagnostic evaluation of smear-negative TB patients.
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ment treatment outcomes of the patients. It is not clear
how many of the patients testing positive for MTB by Xpert
in this study would have been started on TB treatment based
on the clinicians’ decision if Xpert testing was not available.
Among culture- and Xpert-negative cases there may be
false-negative cases that started anti-TB treatment on clinical
grounds and improved—cases that were most likely true TB.
Secondly, all sputum samples received NALC-pretreatment
which could have some effect on direct and bleach-
concentrated Xpert results. Lastly, although the sensitivity
of the Xpert in this study was improved on bleach-
concentrated sputum sample compared with direct sputum,
we had insufficient power to determine whether this differ-
ence was statistically significant.
In conclusion, our results suggest that direct Xpert can
rapidly diagnose TB in smear-negative patients with modest
sensitivity and excellent specificity. Smear-negative TB
patients could benefit from Xpert particularly in those areas
where no culture is available. Testing of single sputum by
Xpert can reach reasonable sensitivity and results would be
available on the same day, avoiding loss of patients and treat-
ment delay. Moreover, bleach concentration and pelleting of
sputum samples improves the sensitivity of Xpert, probably
without affecting the specificity significantly. Further
prospective studies including clinical outcome data (such as
response to treatment) with a larger sample size are required
to clarify these findings.
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